Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.
Mathias Rummel(Universitätsklinikum Gießen und Marburg), Christina Balser(Philipps University of Marburg), Ulrich von Gruenhagen(Praxis für Hämatologie und Onkologie), Ulrich Kaiser(University of Applied Sciences Landshut), Georg Maschmeyer(Radboud University Medical Center), Dorothea Kofahl-Krause(Medizinische Hochschule Hannover), Axel Hinke, N. Niederle(Klinikum Leverkusen), Harald Balló(Praxis für Hämatologie und Onkologie), Juergen Barth(Justus-Liebig-Universität Gießen), Wolfram Brugger(University of Freiburg), Eckhart Weidmann(Krankenhaus Nordwest), Manfred Welslau(Klinikum Aschaffenburg), Gerhard Heil(Goethe University Frankfurt), A. Banat(Justus-Liebig-Universität Gießen), Heinz A. Duerk, Martina Stauch, Christoph Losem
Cited by 50
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k